DE69818987D1 - Zusammensetzung und verfahren zur verzögerung des transports durch biologische membranen - Google Patents

Zusammensetzung und verfahren zur verzögerung des transports durch biologische membranen

Info

Publication number
DE69818987D1
DE69818987D1 DE69818987T DE69818987T DE69818987D1 DE 69818987 D1 DE69818987 D1 DE 69818987D1 DE 69818987 T DE69818987 T DE 69818987T DE 69818987 T DE69818987 T DE 69818987T DE 69818987 D1 DE69818987 D1 DE 69818987D1
Authority
DE
Germany
Prior art keywords
transport
membrane
polymer
biological
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69818987T
Other languages
English (en)
Other versions
DE69818987T2 (de
Inventor
B Rothbard
A Wender
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of DE69818987D1 publication Critical patent/DE69818987D1/de
Application granted granted Critical
Publication of DE69818987T2 publication Critical patent/DE69818987T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • External Artificial Organs (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69818987T 1997-05-21 1998-05-21 Zusammensetzung und verfahren zur verzögerung des transports durch biologische membranen Expired - Fee Related DE69818987T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4734597P 1997-05-21 1997-05-21
US47345P 1997-05-21
PCT/US1998/010571 WO1998052614A2 (en) 1997-05-21 1998-05-21 Composition and method for enhancing transport across biological membranes

Publications (2)

Publication Number Publication Date
DE69818987D1 true DE69818987D1 (de) 2003-11-20
DE69818987T2 DE69818987T2 (de) 2004-07-29

Family

ID=21948441

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69818987T Expired - Fee Related DE69818987T2 (de) 1997-05-21 1998-05-21 Zusammensetzung und verfahren zur verzögerung des transports durch biologische membranen

Country Status (15)

Country Link
US (5) US6306993B1 (de)
EP (1) EP0975370B9 (de)
JP (1) JP2002502376A (de)
KR (1) KR20010012809A (de)
CN (1) CN1263473A (de)
AT (1) ATE251913T1 (de)
AU (1) AU734827B2 (de)
BR (1) BR9809138A (de)
CA (1) CA2291074C (de)
DE (1) DE69818987T2 (de)
ES (1) ES2210761T3 (de)
GB (1) GB2341390B (de)
IL (1) IL132941A0 (de)
PL (1) PL337033A1 (de)
WO (1) WO1998052614A2 (de)

Families Citing this family (312)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1260006A (zh) 1996-02-26 2000-07-12 加利福尼亚州技术学院 双链dna和杂环低聚物之间复合物的形成
US6090947A (en) 1996-02-26 2000-07-18 California Institute Of Technology Method for the synthesis of pyrrole and imidazole carboxamides on a solid support
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP0975370B9 (de) * 1997-05-21 2004-11-03 The Board Of Trustees Of The Leland Stanford Junior University Zusammensetzung und verfahren zur verzögerung des transports durch biologische membranen
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
US6958148B1 (en) * 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US20040063618A1 (en) * 2002-09-30 2004-04-01 Muthiah Manoharan Peptide nucleic acids having improved uptake and tissue distribution
US7306784B2 (en) 1998-06-20 2007-12-11 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
AU755564B2 (en) 1998-06-20 2002-12-12 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US8038984B2 (en) 1998-06-20 2011-10-18 Washington University Membrane-permeant peptide complexes for treatment of sepsis
DK173006B1 (da) * 1998-11-11 1999-11-01 Ke Burgmann As Fremgangsmåde og anlæg til frembringelse af vægmateriale til brug ved fremstilling af kompensatorer, navnlig til røggaskanaler, samt kompensatormateriale og kompensator frembragt ved fremgangsmåden
US6548651B1 (en) 1998-11-11 2003-04-15 Pantheco A/S Modified peptide nucleic acid (PNA) molecules
EP1220902A2 (de) * 1998-11-11 2002-07-10 Pantheco A/S Konjugate zwischen einem peptid und einem analog eine nukleinsäure, wie z.b. ein pna, lna oder morpholino
US7018654B2 (en) * 1999-03-05 2006-03-28 New River Pharmaceuticals Inc. Pharmaceutical composition containing an active agent in an amino acid copolymer structure
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
KR20020021783A (ko) * 1999-04-05 2002-03-22 밀레니엄 파머슈티컬스 인코퍼레이티드 배합물 어레이 및 그의 용도
EP1656945A1 (de) * 1999-06-05 2006-05-17 The Board Of Trustees Of The Leland Stanford Junior University Pharmazeutische Zusammensetzung enthaltend Oligoarginin
IL141250A0 (en) * 1999-06-05 2002-03-10 Univ Leland Stanford Junior Method and composition for inhibiting cardiovascular cell proliferation
AU6502300A (en) * 1999-07-28 2001-02-19 Transform Pharmaceuticals, Inc. Sample arrays and high-throughput testing thereof to detect interactions
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
EP1210121A2 (de) * 1999-08-24 2002-06-05 Cellgate Inc. Verbesserung der verabreichung von medikamenten durch und in epitheliale gewebe durch verwendung von oligoarginine-gruppen
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2001027262A1 (en) * 1999-10-13 2001-04-19 Pantheco A/S Gene selection using pnas
ATE349438T1 (de) 1999-11-24 2007-01-15 Immunogen Inc Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung
US6677153B2 (en) * 1999-11-29 2004-01-13 Avi Biopharma, Inc. Antisense antibacterial method and composition
JP2003518946A (ja) * 2000-01-04 2003-06-17 エイブイアイ バイオファーマ， インコーポレイテッド アンチセンス抗細菌性細胞分裂組成物、およびその方法
US7108970B2 (en) 2000-01-07 2006-09-19 Transform Pharmaceuticals, Inc. Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
US20040252299A9 (en) 2000-01-07 2004-12-16 Lemmo Anthony V. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
AU2001238346A1 (en) 2000-02-15 2001-08-27 Genzyme Corporation Modification of biopolymers for improved drug delivery
US6749865B2 (en) 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
US7078536B2 (en) 2001-03-14 2006-07-18 Genesoft Pharmaceuticals, Inc. Charged compounds comprising a nucleic acid binding moiety and uses therefor
KR20030043785A (ko) 2000-03-16 2003-06-02 젠소프트, 인크. 핵산 결합 부위를 포함하는 하전된 화합물 및 이의 용도
AU2001248281A1 (en) * 2000-04-06 2001-10-23 Pantheco A/S Pharmaceutical composition of modified pna molecules
GB0008563D0 (en) 2000-04-07 2000-05-24 Cambridge Discovery Chemistry Investigating different physical and/or chemical forms of materials
US7049395B2 (en) 2000-05-02 2006-05-23 Yale University Anti-inflammatory compounds and uses thereof
EP1282699B1 (de) 2000-05-04 2012-11-21 Sarepta Therapeutics, Inc. Spleisregion-antisensezusammensetzung und verfahren
EP2364734B1 (de) * 2000-07-21 2017-09-06 ReVance Therapeutics, Inc. Biologische Transportsysteme mit mehreren Komponenten
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
WO2005090392A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based tolerogen compositions and methods of making and using same
US7163918B2 (en) 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US20050059031A1 (en) * 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
ATE536550T1 (de) * 2000-10-06 2011-12-15 Life Technologies Corp Halbleiter nanokristalle enthaltende transfektibare mizellen
US7033597B2 (en) * 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
GB0026924D0 (en) 2000-11-03 2000-12-20 Univ Cambridge Tech Antibacterial agents
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20040063906A1 (en) * 2000-11-24 2004-04-01 Nielsen Peter E. Pna analogues
AU2002216946A1 (en) * 2001-01-05 2002-07-16 Pantheco A/S Modified pna molecules
DE60233137D1 (de) 2001-02-16 2009-09-10 Univ R Transporter mit beabstandeten arginin-teilchen
CA2441484A1 (en) 2001-03-23 2002-10-03 Napro Biotherapeutics, Inc. Molecular conjugates for use in treatment of cancer
US7122626B2 (en) 2001-04-26 2006-10-17 Genesoft Pharmceuticals, Inc. Halogen-substitued thienyl compounds
US6825228B2 (en) 2001-06-13 2004-11-30 Genesoft Pharmaceuticals, Inc. Benzothiophene compounds having antiinfective activity
US6777425B2 (en) 2001-06-13 2004-08-17 Genesoft Pharmaceuticals, Inc. Isoquinoline compounds having antiinfective activity
AU2002312371A1 (en) 2001-06-13 2002-12-23 Roland W. Burli Aryl-benzimidazole compounds having antiinfective activity
WO2002101007A2 (en) 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc Antipathogenic benzamide compounds
US7033991B2 (en) * 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides
US8815793B2 (en) * 2001-07-20 2014-08-26 Northwestern University Polymeric compositions and related methods of use
US7618937B2 (en) * 2001-07-20 2009-11-17 Northwestern University Peptidomimetic polymers for antifouling surfaces
US7858679B2 (en) * 2001-07-20 2010-12-28 Northwestern University Polymeric compositions and related methods of use
JP2004537596A (ja) * 2001-08-03 2004-12-16 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ オリゴグアニジン輸送因子の二方向合成
US20060264608A1 (en) * 2001-08-03 2006-11-23 Wender Paul A Bi-directional synthesis of oligoguanidine transport agents
WO2003014732A1 (en) 2001-08-10 2003-02-20 Symyx Technologies, Inc. Apparatuses and methods for creating and testing pre-formulations and systems for same
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
JP2005523890A (ja) * 2001-10-18 2005-08-11 エッセンシア・バイオシステムズ・インコーポレイテッド 制御放出のための組成物および方法
EP1461084A2 (de) * 2001-12-11 2004-09-29 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport-reagenzien und konjugate
WO2003059192A2 (en) * 2001-12-21 2003-07-24 The Trustees Of Columbia University In The City Of New York C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
DE10201862A1 (de) * 2002-01-18 2003-08-07 Deutsches Krebsforsch Konjugat zur Behandlung prokaryontischer Infektionen
US7026166B2 (en) 2002-01-22 2006-04-11 Chiron Corporation Fluorogenic dyes
WO2003064614A2 (en) * 2002-01-30 2003-08-07 Yale University Transport peptides and uses therefor
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
EP2221377B2 (de) 2002-02-01 2017-05-17 Life Technologies Corporation Doppelsträngige Oligonukleotide
EP1482894A4 (de) * 2002-02-22 2007-08-29 Essentia Biosystems Inc Kosmetische formulierungen mit l-arginin-oligomeren
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US7659253B2 (en) * 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
EP1531844B1 (de) * 2002-02-22 2014-08-20 Shire LLC Neue pharmazeutische verbindungen mit verzögerter freisetzung zur verhinderung von missbrauch kontrollierter substanzen
US7105486B2 (en) * 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7223735B2 (en) * 2003-05-29 2007-05-29 New River Pharmaceuticals Inc. Abuse resistant lysine amphetamine compounds
AU2003223923A1 (en) * 2002-05-01 2003-11-17 Pantheco A/S Peptide nucleic acid conjugates with transporter peptides
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US7794743B2 (en) 2002-06-21 2010-09-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7033602B1 (en) 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
WO2004030610A2 (en) * 2002-07-11 2004-04-15 The Trustees Of Columbia University In The City Of New York Compositions and methods for the intracellular delivery of antibodies
CA2493674A1 (en) 2002-07-19 2004-01-29 The Regents Of The University Of California Dendrimers as molecular translocators
US8911831B2 (en) * 2002-07-19 2014-12-16 Northwestern University Surface independent, surface-modifying, multifunctional coatings and applications thereof
US7498349B2 (en) 2002-08-02 2009-03-03 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
CN100522955C (zh) 2002-08-02 2009-08-05 伊缪诺金公司 含有新型强效紫杉烷的细胞毒性剂及其治疗用途
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
EP1534837A4 (de) * 2002-08-15 2006-09-20 Rima L Mcleod Apicomplexan-wege, inhibitoren und wirkstoffzuf hrung
EE200200531A (et) * 2002-09-17 2004-04-15 O� InBio Terapeutiliste rakkusisenevate antikehade saamineja kasutamine
AU2003285958A1 (en) 2002-10-25 2004-05-25 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
EP1560840B1 (de) 2002-11-05 2015-05-06 Isis Pharmaceuticals, Inc. Zusammensetzungen, die alternierende 2'-modifizierte nucleoside enthalten, zur verwendung in der genmodulation
TR200502189T1 (tr) * 2002-12-09 2007-01-22 American Bioscience, Inc. Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
CA2508769A1 (en) 2002-12-10 2004-06-24 Oscient Pharmaceuticals Corporation Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif
JP4903036B2 (ja) * 2003-01-06 2012-03-21 アンジオケム・インコーポレーテッド 血液脳関門を通過する担体としてのアプロチニンおよび類似体
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
US7704756B2 (en) 2003-01-21 2010-04-27 Novartis Vaccines And Diagnostics, Inc. Fluorogenic dyes
US6969514B2 (en) 2003-02-05 2005-11-29 Soll David B Method for treating elevated intraocular pressure, including glaucoma
US7166692B2 (en) 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
DK2351844T3 (da) 2003-04-29 2014-09-22 Sarepta Therapeutics Inc Præparater til forøgelse af transport- og antisense-effektivitet af nukleinsyreanalog i celler
WO2005000222A2 (en) * 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
CA2532795A1 (en) * 2003-08-07 2005-02-17 Avi Biopharma, Inc. Sense antiviral compound and method for treating ssrna viral infection
US20050222068A1 (en) * 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
CA2540678C (en) * 2003-09-30 2011-02-22 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
US7431915B2 (en) * 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
CA2545679A1 (en) * 2003-11-12 2005-05-26 The University Of Georgia Research Foundation, Inc. Biotin-facilitated transport in gram negative bacteria
US20050234002A1 (en) * 2004-01-23 2005-10-20 Mourich Dan V Antisense oligomers and methods for inducing immune tolerance and immunosuppression
CA2557814A1 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
CN1946431B (zh) 2004-03-03 2011-12-07 雷文斯治疗公司 用于肉毒毒素的局部施用和透皮递送的组合物和方法
KR101284710B1 (ko) * 2004-03-03 2013-07-23 레반스 테라퓨틱스, 아이엔씨. 국소 진단제 및 치료제의 수송을 위한 조성물 및 방법
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
KR100578732B1 (ko) * 2004-03-05 2006-05-12 학교법인 포항공과대학교 분자 수송체로서의 이노시톨 유도체 및 이의 제조방법
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US7402574B2 (en) * 2004-03-12 2008-07-22 Avi Biopharma, Inc. Antisense composition and method for treating cancer
US20050208482A1 (en) * 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
WO2005118884A1 (en) * 2004-05-28 2005-12-15 The United States Of America As Represented By The Secretary Of The Navy A method for the rapid diagnosis of infectious disease by detection and quantitation of microorganism induced cytokines
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
ATE510914T1 (de) 2004-07-02 2011-06-15 Avi Biopharma Inc Antisinn antibakterielle verfahren und verbindungen
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US8043480B2 (en) * 2004-11-10 2011-10-25 The Regents Of The University Of Michigan Methods for forming biodegradable nanocomponents with controlled shapes and sizes via electrified jetting
US8187708B2 (en) * 2004-11-10 2012-05-29 The Regents Of The University Of Michigan Microphasic micro-components and methods for controlling morphology via electrified jetting
US7947772B2 (en) * 2004-11-10 2011-05-24 The Regents Of The University Of Michigan Multiphasic nano-components comprising colorants
JP4690418B2 (ja) * 2004-11-10 2011-06-01 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 多相ナノ粒子
EP1656951A1 (de) * 2004-11-12 2006-05-17 Xigen S.A. Konjugate mit verbesserter Zellaufnahme
AU2005306618B2 (en) * 2004-11-16 2011-03-24 Northwestern University Peptidomimetic polymers for antifouling surfaces
EP1855694B1 (de) * 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Antisense-zusammensetzung zur behandlung von muskelatrophie
DK1988167T3 (da) * 2005-02-17 2020-07-13 Univ Sorbonne Intracellulære inhiberende peptider
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
DK2360258T3 (en) * 2005-02-18 2015-01-12 Angiochem Inc Aprotininpolypeptider to transport a compound of blood-brain-barrier
BRPI0608249A2 (pt) 2005-03-03 2009-12-08 Revance Therapeutics Inc formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
EP1856139B1 (de) 2005-03-03 2011-04-27 Revance Therapeutics, Inc. Zusammensetzungen und methoden zur topischen anwendung und zur transdermalen verabreichung eines oligopeptids
JP2008537739A (ja) * 2005-03-21 2008-09-25 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 新規神経疼痛経路
US20060240032A1 (en) * 2005-03-31 2006-10-26 Hinrichs David J Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases
WO2008036060A2 (en) 2005-04-05 2008-03-27 Allergan, Inc. Clostridial toxin activity assays
KR100699279B1 (ko) * 2005-04-28 2007-03-23 학교법인 포항공과대학교 당 또는 당 유사체를 골격으로 하는 분자 수송체 및 그의제조방법
US7973084B2 (en) * 2005-04-28 2011-07-05 Postech Academy-Industrial Foundation Molecular transporters based on alditol or inositol and processes for the preparation thereof
US20060293268A1 (en) * 2005-05-05 2006-12-28 Rieder Aida E Antisense antiviral compounds and methods for treating foot and mouth disease
US8067571B2 (en) * 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US7790694B2 (en) * 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
EP1907009A4 (de) * 2005-07-15 2009-09-02 Angiochem Inc Verwendung von aprotinin-polypeptiden als träger in pharmazeutischen konjugaten
US7538187B2 (en) * 2005-08-01 2009-05-26 E. I. Du Pont De Nemours And Company Coloring compositions with peptide-based dispersants and binders
US8329668B2 (en) * 2005-09-08 2012-12-11 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
US8524676B2 (en) * 2005-09-08 2013-09-03 Sarepta Therapeutics, Inc. Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7745392B2 (en) * 2005-09-23 2010-06-29 Nitto Denko Corporation Multi-valent guanidinium compounds for enhancing molecular translocation across cellular membranes and epithelial tissues
WO2007038172A2 (en) * 2005-09-23 2007-04-05 Nitto Denko Corporation Guanidinium carriers
US7700565B2 (en) * 2005-09-23 2010-04-20 Nitto Denko Corporation Peptide nucleic acid based guanidinium compounds
AU2006304392B2 (en) 2005-10-18 2014-05-01 National Jewish Health Conditionally immortalized long-term stem cells and methods of making and using such cells
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
JP4944896B2 (ja) 2005-11-17 2012-06-06 ルバンス セラピュティックス インク． 低減された非毒素タンパク質を含むボツリヌス毒素の局所適用及び経皮送達のための組成物及び方法
FI20055653A (fi) * 2005-12-08 2007-06-09 Wallac Oy Leimausreagenssi
FI20065030L (fi) * 2006-01-17 2007-07-18 Wallac Oy Neutraaliset leimausreagenssit ja niistä johdetut konjugaatit
US7732539B2 (en) * 2006-02-16 2010-06-08 National Science Foundation Modified acrylic block copolymers for hydrogels and pressure sensitive wet adhesives
BRPI0708299A2 (pt) * 2006-02-27 2011-05-24 Univ Leland Stanford Junior composições e métodos para o transporte de moléculas com propriedades melhoradas de liberação através de barreiras biológicas
LT2024499T (lt) * 2006-05-10 2018-02-26 Sarepta Therapeutics, Inc. Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų
US8785407B2 (en) * 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
WO2007149310A2 (en) * 2006-06-16 2007-12-27 The Regents Of The University Of Michigan Multiphasic biofunctional nano-components and methods for use thereof
US8563117B2 (en) * 2006-08-04 2013-10-22 Phillip B. Messersmith Biomimetic modular adhesive complex: materials, methods and applications therefore
WO2008019352A1 (en) 2006-08-04 2008-02-14 Nerites Corporation Biomimetic compounds and synthetic methods therefor
US9211340B2 (en) 2006-09-27 2015-12-15 Paolo Botti Means and methods of enhancing delivery to biological systems
BRPI0720730A2 (pt) * 2006-12-29 2014-04-08 Revance Therapeutics Inc Composições e métodos de aplicação tópica e liberação transdérmica de toxinas botulínicas estabilizadas com fragmentos de polipeptídeo derivados de hiv-tat.
JP2010514779A (ja) * 2006-12-29 2010-05-06 ルバンス セラピュティックス インク． 逆配列ｈｉｖ−ｔａｔポリペプチドを用いる輸送分子
WO2008089032A1 (en) * 2007-01-11 2008-07-24 Northwestern University Fouling resistant coatings and methods of making same
US8067532B2 (en) 2007-01-19 2011-11-29 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
GB0702020D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
US8673286B2 (en) 2007-04-09 2014-03-18 Northwestern University DOPA-functionalized, branched, poly(aklylene oxide) adhesives
US8383092B2 (en) * 2007-02-16 2013-02-26 Knc Ner Acquisition Sub, Inc. Bioadhesive constructs
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8664359B2 (en) * 2007-06-03 2014-03-04 Oncotx, Inc. Cancer related isoforms of components of transcription factor complexes as biomarkers and drug targets
ES2694726T3 (es) * 2007-06-29 2018-12-26 Sarepta Therapeutics, Inc. Conjugados peptídicos específicos de tejido y métodos
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
DE102007041655A1 (de) 2007-09-03 2009-03-05 Medicyte Gmbh Vermehrung von primären Zellen und deren Verwendung
ES2313848B1 (es) * 2007-10-24 2010-03-22 Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria Nuevos peptidos antivirales que impiden la union del virus a dlc8.
WO2009099636A1 (en) * 2008-02-07 2009-08-13 The Board Of Trustees Of The Leland Stanford Junior University Conjugation of small molecules to octaarginine transporters for overcoming multi-drug resistance
PL2271670T3 (pl) 2008-03-14 2015-05-29 Allergan Inc Testy aktywności serotypu A toksyny botulinowej oparte na immunologii
DK2279008T3 (en) * 2008-04-18 2019-04-29 Angiochem Inc PHARMACEUTICAL COMPOSITIONS OF PACLITAXEL, PACLITAXEL ANALOGS OR PACLITAXEL CONJUGATES AND RELATED PROCEDURES FOR PREPARATION AND USE
AU2009246876B2 (en) * 2008-05-16 2015-04-02 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
AU2009285547B2 (en) 2008-08-28 2012-05-31 Taiga Biotechnologies, Inc. Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
CN102245642A (zh) 2008-10-15 2011-11-16 安吉奥开米公司 Glp-1激动剂的结合物及其用途
RU2531591C2 (ru) 2008-10-15 2014-10-20 Ангиокем Инк. Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
AU2009322043A1 (en) 2008-12-05 2011-07-07 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
EP2376633A1 (de) * 2008-12-17 2011-10-19 AVI BioPharma, Inc. Antisense-zusammensetzungen und verfahren zur modulation von kontaktüberempfindlichkeit oder kontaktdermatitis
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US9033898B2 (en) 2010-06-23 2015-05-19 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
WO2010101620A2 (en) 2009-03-02 2010-09-10 Seventh Sense Biosystems, Inc. Systems and methods for creating and using suction blisters or other pooled regions of fluid within the skin
US9295417B2 (en) 2011-04-29 2016-03-29 Seventh Sense Biosystems, Inc. Systems and methods for collecting fluid from a subject
US9041541B2 (en) 2010-01-28 2015-05-26 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
PT3281953T (pt) 2009-03-13 2020-01-15 Allergan Inc Ensaios de base imunológica da actividade de endopeptidase redireccionada
EP2406371B1 (de) 2009-03-13 2018-05-09 Allergan, Inc. Für botulinumtoxin-serotyp-a-aktivitätstests auf immunbasis geeignete zellen
CN102405057B (zh) 2009-03-23 2016-05-25 那尼尔科斯治疗公司 用免疫刺激性Hiv Tat衍生物多肽治疗癌症
BRPI1006414A2 (pt) 2009-03-26 2016-02-10 Bl Technologies Inc estrutura de reforço para uma membrana de fibra oca, membrana de fibra oca, método para produzir uma estrutura de reforço e método para produzir uma membrana de fibra oca de reforço
CA2759129C (en) 2009-04-20 2018-12-11 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
CA2764164A1 (en) 2009-06-05 2010-12-09 13Therapeutics, Inc. Immunoregulatory peptides and methods of use
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US9061250B2 (en) 2009-06-26 2015-06-23 Bl Technologies, Inc. Non-braided, textile-reinforced hollow fiber membrane
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
WO2011008996A2 (en) 2009-07-15 2011-01-20 The Regents Of The University Of California Peptides whose uptake in cells is controllable
PT2459208T (pt) * 2009-07-29 2017-01-03 Kai Pharmaceuticals Inc Agentes terapêuticos para redução dos niveis de hormona paratiroideia
CA2779830C (en) * 2009-11-13 2020-07-21 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US20110130465A1 (en) * 2009-12-01 2011-06-02 Nerites Corporation Coatings for prevention of biofilms
JP5457813B2 (ja) * 2009-12-16 2014-04-02 ルネサスエレクトロニクス株式会社 Ａｄｐｌｌ回路、半導体装置及び携帯情報機器
WO2011146390A2 (en) * 2010-05-17 2011-11-24 The Regents Of The University Of California Compositions and methods for in vivo imaging
KR101981705B1 (ko) 2010-05-28 2019-05-24 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
EP2593014B1 (de) 2010-07-16 2015-11-04 Seventh Sense Biosystems, Inc. Niederdruckumgebung für flüssigkeitstransfervorrichtungen
US20130158482A1 (en) 2010-07-26 2013-06-20 Seventh Sense Biosystems, Inc. Rapid delivery and/or receiving of fluids
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US20120039809A1 (en) 2010-08-13 2012-02-16 Seventh Sense Biosystems, Inc. Systems and techniques for monitoring subjects
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
CN103097008B (zh) 2010-09-15 2015-12-09 Bl科技公司 围绕可溶芯体制造纱增强式中空纤维膜的方法
DE102010041958A1 (de) 2010-10-04 2012-04-05 Medicyte Gmbh Geeignete Hepatozyten für in-vitro Genotoxitätstests
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2012050673A1 (en) * 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
WO2012054841A2 (en) 2010-10-22 2012-04-26 The Regents Of The University Of Michigan Optical devices with switchable particles
WO2012064802A1 (en) 2010-11-09 2012-05-18 Seventh Sense Biosystems, Inc. Systems and interfaces for blood sampling
WO2012064821A2 (en) 2010-11-09 2012-05-18 Knc Ner Acquisition Sub, Inc. Adhesive compounds and methods use for hernia repair
US8529814B2 (en) 2010-12-15 2013-09-10 General Electric Company Supported hollow fiber membrane
JP2012131743A (ja) * 2010-12-22 2012-07-12 Kyoto Univ 腫瘍集積型抗癌剤
WO2012138879A2 (en) 2011-04-06 2012-10-11 13Therapeutics, Inc. Peptides for the treatment of hearing
US20130158468A1 (en) 2011-12-19 2013-06-20 Seventh Sense Biosystems, Inc. Delivering and/or receiving material with respect to a subject surface
WO2012149143A1 (en) 2011-04-29 2012-11-01 Seventh Sense Biosystems, Inc. Delivering and/or receiving fluids
EP3236259A1 (de) 2011-04-29 2017-10-25 Seventh Sense Biosystems, Inc. Plasma- oder serumherstellung und entfernung von flüssigkeiten bei reduziertem druck
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
JP6478632B2 (ja) 2011-05-05 2019-03-06 サレプタ セラピューティクス， インコーポレイテッド ペプチドオリゴヌクレオチドコンジュゲート
WO2012177433A1 (en) 2011-06-21 2012-12-27 Evologie Llc Topical compositions for the treatment of dermatological disorders
JP5940542B2 (ja) * 2011-08-31 2016-06-29 国立大学法人 岡山大学 細胞導入ペプチドと皮膚導入促進剤とを組み合わせた皮膚導入システムおよび美白剤
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
TWI429747B (zh) * 2011-11-02 2014-03-11 Univ Nat Taiwan 具修飾側鏈之ｒｎａ病毒衍生胜肽及其用途
EA202090338A1 (ru) 2011-11-18 2021-04-30 Сарепта Терапьютикс, Инк. Функционально-модифицированные олигонуклеотиды и их субъединицы
EP3725333B1 (de) 2011-11-24 2023-08-23 Positec Power Tools (Suzhou) Co., Ltd Peptidsequenzentwurf und verwendung davon für peptid-vermittelte sirna-abgabe
US9321014B2 (en) 2011-12-16 2016-04-26 Bl Technologies, Inc. Hollow fiber membrane with compatible reinforcements
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US9643129B2 (en) 2011-12-22 2017-05-09 Bl Technologies, Inc. Non-braided, textile-reinforced hollow fiber membrane
US9022229B2 (en) 2012-03-09 2015-05-05 General Electric Company Composite membrane with compatible support filaments
ES2644778T3 (es) 2012-03-16 2017-11-30 Merck Patent Gmbh Administración dirigida de lípidos-aminoácidos
MX359736B (es) 2012-03-16 2018-10-09 Merck Patent Gmbh Lipidos de aminoacidos.
US8999454B2 (en) 2012-03-22 2015-04-07 General Electric Company Device and process for producing a reinforced hollow fibre membrane
AU2013249337A1 (en) * 2012-04-17 2014-10-30 Brown University Neuroprotective composition and method of use
US9816066B2 (en) 2012-04-24 2017-11-14 The Regents Of The University Of California Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters
CA2879667C (en) 2012-07-20 2021-11-16 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide
EP2885318A4 (de) 2012-08-14 2016-03-30 Angiochem Inc Peptid-dendrimer-konjugate und ihre verwendungen
US9227362B2 (en) 2012-08-23 2016-01-05 General Electric Company Braid welding
PL2920304T3 (pl) 2012-11-15 2019-07-31 Roche Innovation Center Copenhagen A/S Koniugaty oligonukleotydowe
WO2014120837A2 (en) 2013-01-29 2014-08-07 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellulary releaseable prodrug
WO2014120974A1 (en) 2013-01-30 2014-08-07 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
EP2951305B1 (de) 2013-01-30 2018-08-15 F.Hoffmann-La Roche Ag Lna-oligonukleotid-kohlenhydratkonjugate
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
CN103739674A (zh) * 2013-04-01 2014-04-23 中国人民解放军军事医学科学院野战输血研究所 系列低分子鱼精蛋白模拟肽及其应用
US10370415B2 (en) 2013-04-11 2019-08-06 Carnegie Mellon University Divalent nucleobase compounds and uses therefor
WO2014169216A2 (en) 2013-04-11 2014-10-16 Carnegie Mellon University TEMPLATE-DIRECTED γPNA SYNTHESIS AND γPNA TARGETING COMPOUNDS
KR101447901B1 (ko) * 2013-04-16 2014-10-16 한양대학교 산학협력단 지방세포 표적 비바이러스성 유전자 전달체
JP2016523274A (ja) 2013-06-26 2016-08-08 ザイジェン インフラメーション リミテッド 種々の疾患を処置するためのｊｎｋシグナル伝達経路の新規の細胞透過性ペプチド阻害剤の使用
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
PT3013959T (pt) 2013-06-27 2020-02-04 Roche Innovation Ct Copenhagen As Oligómeros antissentido e conjugados dirigidos para pcsk9
US9663556B2 (en) 2013-10-04 2017-05-30 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV tat derivative polypeptides
GB201401453D0 (en) * 2014-01-28 2014-03-12 Univ Birmingham Transmucosal and transepithelial drug delivery system
GB201401877D0 (en) * 2014-02-04 2014-03-19 Univ Tromsoe Peptides
EP2927685A1 (de) 2014-04-02 2015-10-07 Medicyte GmbH Geeignete Hepatozyten für In-vitro-Hepatitistests
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
KR20160001419A (ko) * 2014-06-27 2016-01-06 포항공과대학교 산학협력단 양이온성 분자 수송체 및 음이온성 생리활성 물질을 포함하는 피부 투과용 조성물
WO2016018917A2 (en) 2014-07-28 2016-02-04 The Regents Of The University Of Califoria Compositions and methods of making polymerized nucleic acids
WO2016023036A1 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California High density peptide polymers
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
EP3302489A4 (de) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. Verfahren und verbindungen zur behandlung von krankheiten und leiden im zusammenhang mit lymphozyten
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
AU2016338410B2 (en) 2015-10-14 2021-07-15 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
US20170283496A1 (en) 2016-03-14 2017-10-05 Roche Innovation Center Copenhagen A/S Oligonucleotides for reduction of pd-l1 expression
US11603369B2 (en) 2016-09-26 2023-03-14 Carnegie Mellon University Divalent nucleobase compounds and uses therefor
EP3548425B1 (de) 2016-12-02 2023-03-29 Taiga Biotechnologies, Inc. Nanopartikelformulierungen
WO2018118599A1 (en) 2016-12-19 2018-06-28 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
FR3064364A1 (fr) * 2017-03-27 2018-09-28 S.P.C.M. Sa Methode de dosage de polymeres cationiques
CN112996486A (zh) 2017-07-17 2021-06-18 K·罗伊兹曼 包含细胞穿透肽的治疗剂的局部递送用于治疗年龄相关性黄斑变性及其它眼病
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CN108822052A (zh) * 2018-05-18 2018-11-16 中国科学技术大学 非肽类多胍小分子和基于非肽类多胍小分子-蛋白质偶联体的蛋白质运输技术
WO2019245353A1 (ko) * 2018-06-22 2019-12-26 재단법인 대구경북과학기술원 사이토카인 융합 폴리펩티드, 및 이를 포함하는 사이토카인 라이브러리
GB201900728D0 (en) * 2019-01-18 2019-03-06 Univ Birmingham Drug delivery system
KR20200110576A (ko) * 2019-03-15 2020-09-24 재단법인대구경북과학기술원 사이토카인 기반 면역세포 및 그의 면역 치료 용도
WO2021002408A1 (ja) 2019-07-02 2021-01-07 Ａｇｃ株式会社 ペプチド及びその製造方法
WO2023048236A1 (ja) 2021-09-22 2023-03-30 Ａｇｃ株式会社 ペプチド

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA209468A (en) * 1921-03-15 Mitchell William Stocking
US4053638A (en) * 1970-05-06 1977-10-11 William Wrigley Jr. Company Anticaries confectioneries and oral health products
US3915800A (en) * 1972-03-30 1975-10-28 Kelco Co Polysaccharide and bacterial fermentation process for its preparation
US4083974A (en) * 1977-03-07 1978-04-11 The Upjohn Company Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether
US4847240A (en) 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
DE2967069D1 (en) 1978-01-16 1984-08-02 Univ Boston Effecting cellular uptake of molecules
US4701521A (en) 1978-07-17 1987-10-20 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4532207A (en) 1982-03-19 1985-07-30 G. D. Searle & Co. Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase
US4880911A (en) 1982-03-19 1989-11-14 G. D. Searle & Co. Fused polypeptides and methods for their detection
US4883661A (en) * 1987-10-09 1989-11-28 Daly John M Use of arginine as an lymphokine synergist
JP2804273B2 (ja) * 1988-03-09 1998-09-24 株式会社メニコン 高含水性眼用レンズ材料
US5241078A (en) * 1988-06-14 1993-08-31 Cetus Oncology Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5162505A (en) 1989-09-19 1992-11-10 Centocor Proteins modified with positively charged carriers and compositions prepared therefrom
DK0506884T3 (da) 1989-12-21 1996-11-04 Whitehead Biomedical Inst Fremgangsmåde til afgivelse af molekyler til eukaryotiske celler
US5576351A (en) * 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
US5115075A (en) * 1990-05-08 1992-05-19 The Dow Chemical Company Amide and hydroxymethyl functionalized polyethers as thermoplastic barrier resins
US5409764A (en) * 1990-07-17 1995-04-25 Toyo Ink Manufacturing Co., Ltd. Curable adhesive composition and sheet thereof
GB9017024D0 (en) * 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
US5633230A (en) 1990-10-24 1997-05-27 Allelix Biopharmaceuticals, Inc. Treatment of cytomegalovirus infection
US5646120A (en) 1990-10-24 1997-07-08 Allelix Biopharmaceuticals, Inc. Peptide-based inhibitors of HIV replication
ES2095959T3 (es) 1990-10-24 1997-03-01 Allelix Biopharma Inhibidores de la replicacion del virus vih a base de peptidos.
US5674849A (en) 1990-10-24 1997-10-07 Allelix Biopharmaceuticals Inc. Anti-viral compositions
US5831001A (en) 1990-10-24 1998-11-03 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
WO1993004701A1 (en) 1991-09-05 1993-03-18 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
CA2134119A1 (en) 1992-04-23 1993-11-11 Michael Twist Treatment of herpesvirus infection
CA2094658A1 (en) * 1992-04-23 1993-10-24 Martin Sumner-Smith Intracellular delivery of biochemical agents
US5434257A (en) * 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
NZ255831A (en) 1992-08-21 1997-04-24 Biogen Inc Fusion proteins comprising biologically active cargo moiety and transport peptides from the hiv tat protein, their preparation and use
EP0599303A3 (de) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide-Konjugate
WO1994014464A1 (en) 1992-12-22 1994-07-07 Allelix Biopharmaceuticals Inc. Synergistic compositions containing an antiviral nucleoside analogue and an antiviral oligopeptide
CA2152373C (en) 1993-10-22 1998-12-15 Michael Twist (Deceased) Treatment of cytomegalovirus infection
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5783178A (en) * 1994-11-18 1998-07-21 Supratek Pharma. Inc. Polymer linked biological agents
AU4690596A (en) 1994-12-30 1996-07-24 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
ZA962455B (en) * 1995-03-31 1996-10-02 B Eugene Guthery Fast acting and persistent topical antiseptic
CA2250295C (en) 1996-03-12 2008-12-30 Pg-Txl Company L.P. Water soluble paclitaxel prodrugs
WO1997040854A2 (en) 1996-05-01 1997-11-06 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5842441A (en) * 1996-08-26 1998-12-01 Pharmalett Denmark A/S Medicated and individualized treatment shampoo for dermatological disturbances of companion animals
EP0975370B9 (de) * 1997-05-21 2004-11-03 The Board Of Trustees Of The Leland Stanford Junior University Zusammensetzung und verfahren zur verzögerung des transports durch biologische membranen

Also Published As

Publication number Publication date
US20020131965A1 (en) 2002-09-19
CN1263473A (zh) 2000-08-16
EP0975370B9 (de) 2004-11-03
CA2291074C (en) 2008-04-01
PL337033A1 (en) 2000-07-31
CA2291074A1 (en) 1998-11-26
WO1998052614A2 (en) 1998-11-26
EP0975370A2 (de) 2000-02-02
ATE251913T1 (de) 2003-11-15
US20030162719A1 (en) 2003-08-28
AU734827B2 (en) 2001-06-21
US6306993B1 (en) 2001-10-23
JP2002502376A (ja) 2002-01-22
GB2341390A (en) 2000-03-15
DE69818987T2 (de) 2004-07-29
KR20010012809A (ko) 2001-02-26
AU7593898A (en) 1998-12-11
BR9809138A (pt) 2001-08-28
US20060111274A1 (en) 2006-05-25
IL132941A0 (en) 2001-03-19
GB9923841D0 (en) 1999-12-08
EP0975370B1 (de) 2003-10-15
WO1998052614A3 (en) 1999-03-18
US6495663B1 (en) 2002-12-17
ES2210761T3 (es) 2004-07-01
GB2341390B (en) 2000-11-08

Similar Documents

Publication Publication Date Title
DE69818987D1 (de) Zusammensetzung und verfahren zur verzögerung des transports durch biologische membranen
DE60233137D1 (de) Transporter mit beabstandeten arginin-teilchen
DE69713499T2 (de) Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
ATE202489T1 (de) Implantat
ATE534732T1 (de) Molekulare targets und zusammensetzungen sowie verfahren zu deren identifikation zur behandlung von degenerations- und entzündungserkankungen
ATE218579T1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin- analogen
DE60335608D1 (de) Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
BG108225A (en) Thiohydantoins and use thereof for treating diabetes
ZA979550B (en) Method for the preparation of methylidene malonate nanoparticles, nanoparticles which optionally contain one or more biologically active molecules, and pharmaceutical compositions containing them.
NO923889L (no) Forbedrede inhibitorer for trombin
EP0743066A3 (de) Wundheilmittel
TNSN04159A1 (fr) Synthese controlee de ziprasidone et compositions en contenant
EA200500300A1 (ru) Цитотоксические агенты, содержащие новые сильнодействующие таксаны, и их терапевтическое применение
ATE315610T1 (de) Verfahren und zusammensetzungen
ATE196255T1 (de) Von einem retroviralen regulationsprotein abstammende, detoxifierte immunogene, dagegen gerichtete antikörper, verfahren zur deren herstellung und diese immunogene oder antikörper enthaltende, pharmazeutische zusammensetzungen.
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
ATE553116T1 (de) Metall bindende verbindungen und ihre verwendungen
ATE274513T1 (de) Verbindungen und verfahren zur behandlung von schmerz
WO2005054303A8 (fr) Dimères de cyclodextrines et leurs dérivés, leurs procédés de préparation et leur utilisation notamment pour la solubilisation de substances pharmacologiquement actives
ATE222758T1 (de) S-alkylisothiouronium-derivate enthaltende pharmazeutische zusammensetzungen
HUP0001218A2 (hu) Eljárás karbamid izolálására, karbamidkompozíciók és eljárás az előállításukra
DE69932719D1 (de) Humanisierte antikörper zur erkennung von verotoxin ii sowie zellinie zur herstellung derselben
ATE340584T1 (de) Zusammensetzung und verfahren zur behandlung chronischer allograft-abstossung
ATE329613T1 (de) Wachstumhormone inhibitoren enthaltende pharmazeutische zubereitungen oder ihre biologisch aktive fragmente zur behandlung von uterinen myomas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee